COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,871 Articles (22,568 medRxiv, 8,303 bioRxiv)

Most recent first Previous |  Page 1631: Articles 16301-16310  | Next

Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study
Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A. G., Martinez-Hernandez, E., Delmestri, A., Verhamme, K., Rijnbeek, P., Duarte-Salles, T., Suchard, M. A., Ryan, P. B., Hripcsak, G., PRIETO-ALHAMBRA, D.
10.1101/2021.03.25.21254315 — Posted: 2021-03-26
On discrete time epidemic models in Kermack-McKendrick form
Diekmann, O., Othmer, H. G., Planque, R., Bootsma, M. C.
10.1101/2021.03.26.21254385 — Posted: 2021-03-26
The acceptability of testing contacts of confirmed COVID-19 cases using serial, self-administered lateral flow devices as an alternative to self-isolation
Love, N. K., Ready, D., Turner, C., Yardley, L., Rubin, G. J., Hopkins, S., Oliver, I.
10.1101/2021.03.23.21254168 — Posted: 2021-03-26
Individual social contact data reflected SARS-CoV-2 transmission dynamics during the first wave in Germany better than population mobility data - an analysis based on the COVIMOD study
Tomori, D. V., Ruebsamen, N., Berger, T., Scholz, S., Walde, J., Wittenberg, I., Lange, B., Mikolajczyk, R., Jaeger, V. K., Karch, A.
10.1101/2021.03.24.21254194 — Posted: 2021-03-26
Uncertainty quantification and sensitivity analysis of COVID-19 exit strategies in an individual-based transmission model
Gugole, F., Coffeng, L. E., Edeling, W., Sanderse, B., de Vlas, S. J., Crommelin, D.
10.1101/2021.03.24.21254218 — Posted: 2021-03-26
SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma donors
Clara Di Germanio, C. D., Simmons, G., Kelly, K., Martinelli, R., Darst, O., Azimpouran, M., Stone, M., Hazegh, K., Grebe, E., Zhang, S., Ma, P., Orzechowski, M., Livny, J., Hung, D. T., Vassallo, R. R., Busch, M. P., Dumont, L. J.
10.1101/2021.03.24.21254260 — Posted: 2021-03-26
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
Byttebier, G., Belmans, L., Alexander, M., Saxberg, B. E. H., De Spiegeleer, B., De Spiegeleer, A., Devreker, N., Van Praet, J., Vanhove, K., Reybrouck, R., Wynendaele, E., Fedson, D.
10.1101/2021.03.24.21252687 — Posted: 2021-03-26 Discussion: Onsite
Dramatic drop of new SARS-CoV-2 infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine
Guijarro, C., Galan, I. M., Perez-Fernandez, E., Martinez-Ponce, D. C., Goyanes, M. J., Castilla, V., Velasco, M.
10.1101/2021.03.24.21254238 — Posted: 2021-03-26
ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study
Iniguez, M., Perez-Matute, P., Villoslada-Blanco, P., Recio-Fernandez, E., Ezquerro-Perez, D., Alba, J., Ferreira-Laso, M. L., Oteo, J. A.
10.1101/2021.03.24.21253576 — Posted: 2021-03-26
Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting rapid test
Ducrest, P. J.
10.1101/2021.03.25.21252280 — Posted: 2021-03-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).